Skip to Main Content

Paper Details

A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma.
Cancer Res Commun
3
2023
Bevacizumab, CD4, CD4 T cell, CD4 T cell EMRA, GBM, ICI, MICA, MICB, PD-L1, Patients, Recurrent Glioblastoma, T cells, T-cell, VEGF-A, adaptive and innate immune cells, bevacizumab, dismal, glioblastoma, human, immune cell, immune cells, patient, patients, recurrent, steroid, steroids
Author NameAffiliation
Kambiz NaelDavid Geffen School of Medicine, University of California Los Angeles
Nadejda M TsankovaMount Sinai Medical Center
Sacha Gnjaticand Pathology and Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Sacha Gnjaticand Pathology and Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-Schulzeand Pathology and Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-Schulzeand Pathology and Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 6

Datasets

Release 1.2